KEGG pathway enrichment analysis showed that these potential therapeutic targets of solasonine for BC were significantly enriched in three pathways (adjusted P-value ≤ 0.05), including proteoglycans in cancer, HIF-1 signaling pathway, and Yersinia infection. This evidence concerns the gene HIF1A and Yersinia infectious disease.